Global Autonomous Corporation (GAC), a Subsidiary of Alpine 4 Holdings Nasdaq: (ALPP), Establishes a Presence in the United Arab Emirates

PHOENIX, AZ / ACCESSWIRE / May 8, 2023 / Alpine 4 Holdings, Inc. (NASDAQ:ALPP), a leading operator and owner of small market businesses, announces that its subsidiary, Global Autonomous Corporation (GAC) has selected Dubai, United Arab Emirates, as its first international point. The Company is working towards the deployment of the GAC Fulfillment Delivery Network in and around Dubai, dubbed “The City of the Future,” as they have a proven willingness to adopt new and emerging concepts and technologies. The Alpine 4 Executive Team are in Dubai May 8th-15th to establish a new office in the heart of Dubai’s technology epicenter, near the Burj Khalifa, that will support strategic business functions, including kiosk operations, flight management and business infrastructure. Additionally, Alpine 4 /GAC’s UAE based consultants, Ghani Consulting, have set up meetings with top officials within several agencies and authorities including: the Dubai Civil Aviation Authority, Dubai Smart City and Silicon Oasis, Dubai Roads and Transportation Authority, Dubai Police Ports, Dubai Small Medium Enterprise, H.E Helal Saeed Almarri, General Manager of Dubai’s Economy and Tourism Authority, and the Dubai Future Foundation to further the initiatives of GAC. As GAC expands into Dubai and throughout the UAE, the Company seeks to add Dubai’s highly skilled local workforce as it aims to immediately add executives and support staff to meet GAC’s growth initiatives, subsequently supporting the local economy of Dubai.

Kent Wilson, CEO of Alpine 4 and Global Autonomous Corporation had this to say, “After visiting Dubai in late September 2022, the Company concluded that Dubai, and by a larger part, the UAE, represents an ideal host city and country for the inaugural deployment of the GAC Mesh Fulfillment Network due to their regulatory desire and potential user base to see these technologies deployed. We also understood the magnitude of choosing Dubai as the first city to receive the GAC Mesh Fulfillment Network, as the City’s commitment to embracing new technologies is second to none around the world. This is the perfect environment to showcase our Vayu Aerospace American Made G1 Drones to the UAE and future US-2’s. I want to personally say thank you to all the hard-working groups that have brought us to this point; we look forward to a long and prosperous relationship with Dubai and the UAE.”

To lean more about the various agencies and authorities the Alpine Team will be meeting with, visit:

About Global Autonomous Corporation: Global Autonomous Corporation’s (GAC) mission is direct and resolute. Create a simple, pleasant, and meaningful user experience to deliver goods autonomously.

About Alpine 4 Holdings: Alpine 4 Holdings, Inc. is a Nasdaq traded Holding Company (trading symbol: ALPP) that acquires business, wholly, that fit under one of several portfolios: Aerospace, Defense Services, Technology, Manufacturing or Construction Services as either a Driver, Stabilizer or Facilitator from Alpine 4’s disruptive DSF business model. Alpine 4 works to vertically integrate the various subsidiaries with one another even if from different industries. Alpine 4 understands the nature of how technology and innovation can accentuate a business, focusing on how the adaptation of new technologies, even in brick-and-mortar businesses, can drive innovation. Alpine 4 also believes that its holdings should benefit synergistically from each other, have the ability to collaborate across varying industries, spawn new ideas, and create fertile ground for competitive advantages.

Four principles at the core of our business are Synergy. Innovation. Drive. Excellence. At Alpine 4, we believe synergistic innovation drives excellence. By anchoring these words to our combined experience and capabilities, we can aggressively pursue opportunities within and across vertical markets. We deliver solutions that not only drive industry standards, but also increase value for our shareholders.

Contact: Investor Relations

Forward-Looking Statements: Certain statements and information in this press release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. The information disclosed in this press release is made as of the date hereof and reflects Alpine 4 most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Alpine 4 believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Alpine 4 disclaims any intention or obligation to update the forward-looking statements for subsequent events.

Other factors that may affect our businesses include global economic trends, competition and geopolitical risks, including changes in the rates of investment or economic growth in key markets we serve, or an escalation of sanctions, tariffs or other trade tensions between the U.S. and China or other countries, and related impacts on our businesses’ global supply chains and strategies; market developments or customer actions that may affect demand and the financial performance of major industries and customers we serve, such as secular, cyclical and competitive pressures in our Technology, Construction and Manufacturing businesses; pricing, the timing of customer investment and other factors in these markets; demand for our products or other dynamics related to the COVID-19 pandemic; conditions in key geographic markets; and other shifts in the competitive landscape for our products and services; changes in law, regulation or policy that may affect our businesses, such as trade policy and tariffs, regulation and the effects of tax law changes; our decisions about investments in research and development, and new products, services and platforms, and our ability to launch new products in a cost-effective manner; our ability to increase margins through implementation of operational changes, restructuring and other cost reduction measures; the impact of actual or potential failures of our products or third-party products with which our products are integrated, and related reputational effects; the impact of potential information technology, cybersecurity, or data security breaches at Alpine 4, our subsidiaries or third parties; and the other factors that are described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, as updated in our Quarterly Reports on Form 10-Q.

SOURCE: Alpine 4 Holdings, Inc.

Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.

“Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology to discover new medicines faster. The strategic acquisitions of Cyclica and Valence add industry-leading capabilities in digital chemistry, as well as machine-learning and artificial intelligence, which combined with our large-scale automated wet-laboratories and supercomputing capabilities, enables us to deploy what I believe is the most complete, technology-enabled drug discovery solution in the biopharma industry. We look forward to showing the world proof of the compounding benefit of this full-stack approach through the rapid acceleration of our pipeline and partnerships. Amidst a rapidly accelerating global race for technology talent, these acquisitions cement Recursion as the center of gravity for the best and brightest in ML and AI who want to reimagine how drugs are discovered,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “I am so excited to welcome the Cyclica and Valence teams to Recursion, especially at such a dynamic moment in history when machine learning and artificial intelligence are creating so much rapid change across every industry.”

Cyclica, headquartered in Toronto, has built two highly differentiated products in the digital chemistry space which will be integrated into the RecursionOS. MatchMaker™ is an AI-enabled deep learning engine that predicts the polypharmacology of small molecules as the foundation for small molecule drug discovery. It is able to generalize across the proteome and uses both AlphaFold2 structures and homology models. POEM™ (Pareto Optimal Embedding Model) is a unique similarity-based property prediction model. In contrast to other AI prediction models, POEM uses multiple types of molecular fingerprints to describe molecules, providing a much richer measure of similarity that leads to greater accuracy.

“Cyclica and Recursion both believe in the value of industrializing drug discovery,” said Naheed Kurji, CEO and Co-Founder of Cyclica. “Combining our proteome-wide prediction of small molecule-target interactions into Recursion’s data universe will create one of the largest fit-for-purpose biological and chemical datasets in the drug discovery space. Together, I believe Recursion will have an immense impact on human health in the years to come.”

Valence, headquartered in Montréal at Mila, the world’s largest deep learning research institute, is committed to unlocking the full potential of deep learning in the drug discovery process. The company has pioneered the application of low-data learning in drug design, unlocking the ability to design differentiated small molecules with improved properties and function from datasets too small, sparse, or noisy for traditional deep learning methods. Valence has an unparalleled track record of innovation in molecular machine learning, including best-in-class methods for AI-enabled structural biology, generative chemistry, and multi-parametric optimization, ultimately enabling the design of best-in-class or first-in-class chemistry against challenging biology.

“The integration of Valence’s powerful AI-based chemistry engine into Recursion’s diverse and data-rich operating system will help unlock the true power of AI-first digital chemistry and drug discovery,” said Daniel Cohen, CEO and Co-founder at Valence Discovery. “Recursion is a leader in technology-enabled drug discovery with a proven track record of leveraging data to uncover novel biology, and I’m thrilled for our teams to join forces and combine our respective strengths to rapidly advance new medicines to patients who need them.”

Joining forces with Recursion’s Montréal deep learning research office, Valence will become an artificial intelligence and machine learning research center to be led by Daniel Cohen with continued advisory from Yoshua Bengio.

“The acquisition of Valence gives Recursion the opportunity to create a true center of excellence for some of the most compelling AI/ML research in the world,” said Yoshua Bengio, deep learning pioneer and scientific advisor to both Recursion and Valence. “With this newly integrated group housed in the Mila ecosystem, Recursion’s team of researchers in AI and ML for drug discovery reaches a critical mass at a crucial time in the development of new AI algorithms for scientific discovery.”

Terms of the Acquisitions

Recursion has entered into agreements to acquire Cyclica for a purchase price of $40 million and Valence for a purchase price of $47.5 million, in each case subject to customary closing and post-closing purchase price adjustments. The purchase price in the acquisitions will be payable in the form of shares of Recursion Class A common stock, shares of a subsidiary of Recursion exchangeable for shares of Recursion’s Class A common stock and the assumption of certain outstanding Valence and Cyclica options. In certain limited circumstances, Recursion may pay nominal cash consideration to Valence and Cyclica shareholders in lieu of such exchangeable shares or Recursion Class A common stock. Recursion expects no material change to its cash runway as a result of these acquisitions. Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at, or connect on Twitter and LinkedIn.

About Cyclica
As a neo-biotech, Cyclica is efficiently advancing an industry-leading, robust and sustainable drug discovery portfolio focused on CNS, oncology, and auto-immune diseases. Cyclica has built the only generalizable platform across the entire proteome, expanding the target space for low-data targets, including AlphaFold2 structures, PPIs, and mutant oncogenic targets. Cyclica has brought together a diverse and experienced team of biologists, chemists, computer scientists, and business professionals who are collectively passionate about changing the drug discovery paradigm. By exploring the unexplored, and drugging the undrugged, Cyclica strives to impact patient health like never before. For more information, please visit:

About Valence Discovery
Valence is harnessing a revolution in computation to improve human health. The company is a leader in developing and deploying AI and physics-based technologies to enable the design of differentiated small molecules with improved properties and function. Following successful partnerships with leading biotech and pharmaceutical companies, and an unparalleled track record of innovation featured in top AI journals and conferences, Valence has built a team of interdisciplinary industry veterans and computational experts focused on rapidly advancing a portfolio of internal drug discovery programs. Valence launched publicly in 2021, is supported by leading biotech and deeptech investors, and is headquartered in Montréal. To learn more, please visit

Media Contact

Investor Contact

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing and completion of the Cyclica and Valence acquisitions and the outcomes and benefits expected from such acquisitions; Recursion OS and other technologies; business and financial plans and performance, including cash runway; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 8833750

Europe’s largest nuclear power plant dormant – governor

Russia’s Zaporozhye Nuclear Power Plant has been put into a dormant state, the interim governor of Zaporozhye Region, Evgeniy Balitsky, has declared. The decision to halt the station’s work was made due to the threat of “unpredictable” actions by Kiev, the official said on Monday.

“We understand that this is a manipulation. Therefore, the nuclear reactors have now been powered down. The fifth reactor is on hot standby. We do not understand what this monkey with a grenade can perform, so we have powered down the reactors,” Balitsky told the Crimea 24 TV channel.

The reactor blocks were shut down last week, with their maintenance “continuing in accordance with all necessary regulations, with strict control of radiation safety standards,” the director of the nuclear plant, Yuri Chernichuk, said on Friday.

Concerns over the safety of the Zaporozhye installation have skyrocketed as of late amid the looming, long-hyped Ukrainian counteroffensive. The security situation in the area near the facility was “becoming increasingly unpredictable and potentially dangerous,” International Atomic Energy Agency (IAEA) Director General Rafael Mariano Grossi warned on Saturday.

“I’m extremely concerned about the very real nuclear safety and security risks facing the plant. We must act now to prevent the threat of a severe nuclear accident and its associated consequences for the population and the environment,” he said.

Russian troops took control of Europe’s largest nuclear power plant in March 2022. A subsidiary of Moscow’s state-owned nuclear energy giant Rosatom formally assumed management of the plant last fall, when Zaporozhye Region voted to join Russia along with Kherson, Donetsk and Lugansk.

The nuclear facility has become the target for repeated artillery shelling and drone attacks by Kiev’s forces. Apart from that, the Ukrainian military has repeatedly staged landing operations across the Dnepr River in an apparent attempt to seize the facility. So far, such attacks have been unsuccessful, and the station itself did not sustain critical damage, which may potentially result in a major nuclear catastrophe.

Source: Russia Today

Palestinian students learn in tents after school demolished by Israel

Dozens of Palestinian students gathered in tents on Monday to receive lessons after their school was demolished by the Israeli army in the occupied West Bank. On Sunday, the Israeli army tore down a European Union-funded primary school in the town of Jibb Al-Deeb, east of Bethlehem city, citing lack of a construction permit. The school was located in Area C of the West Bank, which is under Israeli army control and was first demolished by Israel in 2017. 'More than 60 students resumed their lessons today in two big tents,' Hassan Brijieh, head of the so-called Colonization and Wall Resistance Commission in Bethlehem, told Anadolu. He said the tents were erected by activists to allow students to receive their lessons after the school was demolished by Israeli forces. The EU said it was 'appalled' by Israel's demolition of the Palestinian school. 'Demolitions are illegal under international law, and children's right to education must be respected,' the office of the EU representative to the Palestinian Territories said in a statement. The EU called on Israel to 'halt all demolitions and evictions, which will only increase the suffering of the Palestinian population and further escalate an already tense environment.' Israel widely uses the pretext of lack of construction permits to demolish Palestinian homes, especially in Area C. Under the 1995 Oslo Accords between Israel and the Palestine Liberation Organization (PLO), the West Bank, including East Jerusalem, was divided into three portions - Area A, B and C. *Writing by Ahmed Asmar

Source: Anadolu Agency

Former Turkish state minister for economy dies at 74

A well-known economist and former Turkish State Minister of Economic Affairs Kemal Dervis died on Monday at the age of 74. Dervis was receiving treatment in the US for a long time due to his illness. He was born in Istanbul in 1949 and received his Bachelor's and Master's degrees in economics from the London School of Economics, and his PhD from Princeton University in the US. He began his career at the World Bank in 1977 and became vice president for the Middle East and North Africa in 1996. Amid the financial crisis, he was appointed Trkiye's state minister for economy in March 2001. In 2001-2002, Dervis was responsible for launching a reform program while negotiating with the IMF, and later in the country's general elections on Nov. 3, 2002, he was elected member of parliament from the Republican People's Party (CHP). After resigning from parliament in 2005, he served the United Nations Development Program (UNDP) as president until 2009.

Source: Anadolu Agency

EU to assess position on Syria after Arab League’s readmission

The EU on Monday said members will discuss their position towards Syria after the Arab League reinstated the country's membership. Officials will assess this week the decision of the Arab League on readmitting Syria and its 'potential implications' for EU foreign policy, Peter Stano, the bloc's spokesperson for foreign affairs, told reporters. He explained that EU foreign policy chief Josep Borrell will hold talks 'with the partners in the region to see the reasons for this decision or expectations from this decision.' Stano recalled that the EU currently rules out the normalization of relations with the Assad regime and the lifting of sanctions 'unless there is a movement towards a political solution in line with the relevant UN Security Council resolutions' and 'stopping the persecution and oppression of Syrian people.' He stressed that the EU's 'position is not dogmatic' and diplomats will discuss if the 27 members are in consensus to adjust to this approach. Arab League on Sunday decided to reinstate Syria's membership after 12 years of suspension over the regime's brutal crackdown on pro-democracy protests, which led to a civil war. Germany rules out normalization 'for now' Meanwhile, Germany said appropriate conditions were not in place to normalize relations with Syria. The Syrian regime continues to block any progress in the political process and commits the most serious human rights violations against its own people on a daily basis, Foreign Ministry spokesman Christofer Burger told a regular press on Monday. "In this respect, unfortunately, nothing has changed in the reality on the ground, which would allow us to provide support, for example for reconstruction, to lift sanctions and, from our point of view, there are currently no prerequisites for a dignified return of refugees." *Oliver Towfigh Nia contributed to this story from Berlin

Source: Anadolu Agency

Moldova’s breakaway Transnistria asks Russia to increase number of peacekeepers in region

Moldova's breakaway region of Transnistria said its authorities are asking Russia to increase the number of peacekeepers in the region. 'Peacekeepers are the main security factor on the (banks of the) Dniester," and they pose "the main obstacle" against Ukraine and Moldova, head of the breakaway region's representative office in Moscow Leonid Manakov told Russia's RIA news agency in an interview. "As long as Russia's peacekeeping mission continues, Moldova is shackled in any military plans and preparations against Transnistria,' he added. During the interview, Manakov claimed that Russia reduced the size of its peacekeeping contingent from six to two motorized rifle battalions, and that the current number of Russian peacekeepers in the region does not exceed 450. He also claimed that 3,100 personnel are supposed to be present according to the staff of the Joint Control Commission (JCC) -- joint force in the region comprising Russian, Moldovan, and Transnistrian peacekeepers -- and that it is legally possible to increase the Russian contingent. "There is such an option, and it is justified from the point of view of worsening security risks, including the terrorist threat, and at the same time, it is legally justified by the documents adopted as part of the activities of the JCC," Manakov further claimed, adding that this is possible at the expense of Russians permanently residing in the breakaway region. Transnistria is an unrecognized breakaway region, which is internationally recognized as part of Moldova but has been controlled by pro-Russian separatists since a two-year conflict in 1990-1992. A cease-fire agreement was signed in July 1992 between Chisinau and Moscow following the conflict, which installed a peacekeeping force in the region made up of Russian, Moldovan, and Transnistrian forces tasked with observing the cease-fire and other security arrangements.

Source: Anadolu Agency